Tardiff B E, Califf R M, Morris D, Bates E, Woodlief L H, Lee K L, Green C, Rutsch W, Betriu A, Aylward P E, Topol E J
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
J Am Coll Cardiol. 1997 Feb;29(2):240-9. doi: 10.1016/s0735-1097(96)00492-5.
This study sought to investigate the impact of surgical revascularization on outcome after myocardial infarction.
Small variations in rates of coronary artery bypass graft surgery (CABG) were noted among thrombolytic regimens in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, prompting the question of whether survival differences were partly related to differences in CABG rates.
Patients in the GUSTO trial were randomized to one of four thrombolytic strategies. Of 40,861 patients with complete data, 3,526 underwent surgical revascularization during their initial hospital admission. Thirty-day and 1-year mortality rates were estimated using Kaplan-Meier techniques, and the impact of CABG as a time-dependent covariate on death was evaluated using a Cox survival model, adjusting for baseline prognostic factors.
The median time from study enrollment to CABG was 7 days across treatment groups. A 15% reduction in mortality for the tissue-type plasminogen activator (t-PA)-treated group was evident by the seventh day. Bypass surgery was a significant independent predictor of 30-day mortality (risk ratio 1.87) and a weaker predictor of 1-year mortality (risk ratio 1.21). Operative mortality was highest in patients with acute mitral regurgitation, ventricular septal defect or poor left ventricular function and in those undergoing CABG within the first 4 days of randomization.
The survival benefit of accelerated t-PA was not related to surgical revascularization. Bypass surgery was associated with excess mortality in the first year, but the added short-term mortality associated with CABG may be balanced by anticipated long-term benefit in specific groups of patients.
本研究旨在调查外科血管重建术对心肌梗死后结局的影响。
在全球应用链激酶和组织型纤溶酶原激活剂治疗闭塞冠状动脉(GUSTO)试验中,溶栓方案之间冠状动脉旁路移植术(CABG)的发生率存在微小差异,这引发了生存率差异是否部分与CABG发生率差异有关的问题。
GUSTO试验中的患者被随机分配到四种溶栓策略之一。在40861例有完整数据的患者中,3526例在首次住院期间接受了外科血管重建术。使用Kaplan-Meier技术估计30天和1年死亡率,并使用Cox生存模型评估CABG作为时间依赖性协变量对死亡的影响,并对基线预后因素进行调整。
各治疗组从研究入组到CABG的中位时间为7天。到第7天时,组织型纤溶酶原激活剂(t-PA)治疗组的死亡率明显降低了15%。搭桥手术是30天死亡率的显著独立预测因素(风险比1.87),而对1年死亡率的预测作用较弱(风险比1.21)。急性二尖瓣反流、室间隔缺损或左心室功能差的患者以及在随机分组后前4天内接受CABG的患者手术死亡率最高。
加速使用t-PA的生存获益与外科血管重建术无关。搭桥手术在第一年与额外的死亡率相关,但CABG相关的短期额外死亡率可能会被特定患者群体预期的长期获益所平衡。